Quantcast
Last updated on April 24, 2014 at 11:16 EDT

Latest Basal Stories

2014-01-29 12:27:15

LAUSANNE, Switzerland, January 29, 2014 /PRNewswire/ -- Click here for Picture 1 [http://www.debiotech.com/news/images/nw181_1.png ] The JewelPUMP2, which will be unveiled for the first time at the ATTD 2014 congress on February 5th in Vienna, is a new product dedicated to the Diabetes Type 2 market, based on Debiotech's innovative JewelPUMP platform. The JewelPUMP2 has been entirely re-designed to address the very specific market of Type 2 patients, requiring an...

2013-06-22 12:21:35

- EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus® - PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus(® )(insulin glargine [rDNA origin] injection). The company also announced topline...

2012-12-05 08:27:38

ARAD, Israel, December 5, 2012 /PRNewswire/ -- Andain Inc [http://www.andaininc.com ]. (OTCQB: ANDN [http://finance.yahoo.com/q?s=ANDN ]) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields, today discussed its breakthrough miniature fully disposable and programmable insulin pump. Andain's miniature insulin pump [http://www.andaininc.com/Default.asp?sType=0&PageId=15 ] is an ultra slim,...

2012-07-18 10:26:45

INDIANAPOLIS, July 18, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Accu-Chek Combo system for insulin pump therapy. The Accu-Chek Combo system seamlessly combines a blood glucose meter with an insulin pump, which are able to exchange data in both directions via Bluetooth wireless technology. The meter not only enables the user to quickly test blood glucose levels: It allows for...

2011-09-12 06:30:00

BRIDGEWATER, N.J., Sept. 12, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it has completed a significant Series C round of financing of $150 million. This financing will support the commercialization of the V-Go(TM) Disposable Insulin Delivery Device, which provides basal-bolus insulin therapy for adult patients with diabetes who require insulin. Welsh, Carson,...

2011-07-25 06:30:00

BRIDGEWATER, N.J., July 25, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go(TM) Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification. The V-Go is designed to provide simple basal-bolus therapy for adults who require insulin therapy. "These are important corporate milestones for...

2011-06-27 07:30:00

SAN DIEGO, June 27, 2011 /PRNewswire/ -- Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego. Data were from two, phase three, 52-week clinical trials, one with individuals with type 1 and one in individuals with type 2 diabetes. To...

2011-03-01 06:30:00

BRIDGEWATER, N.J., March 1, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the U.S. Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog® for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients...

2010-07-12 18:00:00

DANBURY, Conn., July 12 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug...

2010-06-25 17:15:00

ORLANDO, Fla., June 25 /PRNewswire-FirstCall/ -- Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1) These phase 2 studies showed that insulin degludec helped improve glucose control. In...